Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W A Breeman

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1995
Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in ratsW A Breeman, D J Kwekkeboom, P P Kooij, et al.
International Journal of Cancer|October 16, 1999
Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphyW A Breeman, M De Jong, B F Bernard, et al.
International Journal of Cancer|May 8, 2001
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapyM de Jong, W A Breeman, B F Bernard, et al.
Life Sciences|January 1, 1991
In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsW H Bakker, E P Krenning, J C Reubi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1990
Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animalsW H Bakker, E P Krenning, W A Breeman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1992
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotideE P Krenning, W H Bakker, P P Kooij, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|March 25, 2000
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analoguesM De Jong, W A Breeman, H F Bernard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1991
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in manW H Bakker, E P Krenning, W A Breeman, et al.
European Journal of Nuclear Medicine|August 1, 1993
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsE P Krenning, D J Kwekkeboom, W H Bakker, et al.
International Journal of Cancer|February 10, 1998
Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapyM De Jong, W H Bakker, W A Breeman, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 1995
Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in ratsW A Breeman, D J Kwekkeboom, P P Kooij, et al.
International Journal of Cancer|October 16, 1999
Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphyW A Breeman, M De Jong, B F Bernard, et al.
International Journal of Cancer|May 8, 2001
[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapyM de Jong, W A Breeman, B F Bernard, et al.
Life Sciences|January 1, 1991
In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in ratsW H Bakker, E P Krenning, J C Reubi, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 1, 1990
Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animalsW H Bakker, E P Krenning, W A Breeman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 1, 1992
Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotideE P Krenning, W H Bakker, P P Kooij, et al.
The Quarterly Journal of Nuclear Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR)|March 25, 2000
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analoguesM De Jong, W A Breeman, H F Bernard, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 1, 1991
In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in manW H Bakker, E P Krenning, W A Breeman, et al.
European Journal of Nuclear Medicine|August 1, 1993
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patientsE P Krenning, D J Kwekkeboom, W H Bakker, et al.
International Journal of Cancer|February 10, 1998
Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapyM De Jong, W H Bakker, W A Breeman, et al.
Pageof 6